Targeting resistant lesions in advanced prostate cancer to improve treatment outcomes
Project 3: Extending Clinical Benefit by Selective Treatment of Resistant Lesions in mCRPC
This study is looking at men with advanced prostate cancer who are not responding well to their current treatments, and it aims to find and target the stubborn areas of cancer that aren't improving, using special imaging and focused radiation therapy to help make the overall treatment more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10899413 on NIH RePORTER |
What this research studies
This research focuses on men with metastatic castration-resistant prostate cancer (mCRPC) who are experiencing disease progression despite ongoing treatment. The study aims to identify specific lesions that have developed resistance to therapy while the majority of lesions continue to respond. By using advanced imaging techniques, researchers will selectively treat these resistant lesions with localized ablative therapies, such as stereotactic body radiation therapy, to potentially extend the effectiveness of existing systemic treatments. The approach involves detailed imaging assessments and modeling to optimize treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who are experiencing disease progression but still have responding lesions.
Not a fit: Patients who do not have metastatic castration-resistant prostate cancer or those whose disease is not progressing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and prolonged survival for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in using localized therapies for resistant lesions, indicating potential for success with this novel approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Jeraj, Robert — University of Wisconsin-Madison
- Study coordinator: Jeraj, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.